Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04239092 · ClinicalTrials.gov registry record · Phase 1
9-ING-41 in Pediatric Patients With Refractory Malignancies.
A Phase 1 study, sponsored by Actuate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04239092 is a Phase 1 study that was terminated before completion, run by Actuate Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT04239092, a Phase 1 study, was terminated before completion, sponsored by Actuate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
Interventions
- DRUG Cyclophosphamide
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG Topotecan
- DRUG 9-ING-41
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-06-05 |
| Est. Completion | 2025-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04239092
The ClinicalTrials.gov registry entry for NCT04239092 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actuate Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04239092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04239092 about?
NCT04239092 is a clinical study titled "9-ING-41 in Pediatric Patients With Refractory Malignancies.". 9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
What is the current status of trial NCT04239092?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-06-05. Estimated completion is 2025-07-07.
What interventions are being tested in trial NCT04239092?
The interventions under investigation include: Cyclophosphamide (DRUG), Temozolomide (DRUG), Irinotecan (DRUG), Topotecan (DRUG), 9-ING-41 (DRUG).
Who is sponsoring clinical trial NCT04239092?
This trial is sponsored by Actuate Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.